The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
A correction has been published: N Engl J Med 1997;336(14):1039.

Original Article
Brief Report
PreviousPrevious
Volume 336:263-265 January 23, 1997 Number 4
NextNext

Successful Treatment of a Patient with a Thymoma and Pure Red-Cell Aplasia with Octreotide and Prednisone
Giovannella Palmieri, M.D., Secondo Lastoria, M.D., Annamaria Colao, M.D., Ph.D., Emilia Vergara, M.D., Paola Varrella, M.D., Edoardo Biondi, M.D., Carmine Selleri, M.D., Lucio Catalano, M.D., Gaetano Lombardi, M.D., Angelo Raffaele Bianco, M.D., and Marco Salvatore, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
-PubMed Citation
Thymomas are rare epithelial neoplasms frequently associated with myasthenia gravis, hypogammaglobulinemia, and pure red-cell aplasia.1,2,3,4,5,6,7,8,9,10,11 In pure red-cell aplasia, autoantibodies against early and late erythroid-cell progenitors or erythropoietin, as well as inhibitory cellular immune mechanisms, have been implicated.9,10,11 Limited information suggests that patients with pure red-cell aplasia and thymoma have a poor prognosis.6,7,10

We recently demonstrated a high uptake of indium-labeled octreotide (111In-DTPA-d-Phe1-octreotide) in thymomas, a phenomenon related to the high content of somatostatin receptors in these tumors.12 The same labeling method has been successful in imaging a wide variety of neuroendocrine tumors.13,14 Sixteen of 17 thymomas we . . . [Full Text of this Article]

Case Report

Discussion


Source Information

From the Department of Molecular and Clinical Oncology and Endocrinology (G.P., A.C., E.B., G.L., A.R.B.) and the Department of Hematology (C.S., L.C.), School of Medicine, Federico II University; and the Department of Nuclear Medicine, National Cancer Institute G. Pascale (S.L., E.V., P.V., M.S.) — both in Naples, Italy.

Address reprint requests to Dr. Palmieri at Via S. Pansini 5, 80131 Naples, Italy.

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.